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There are numerous biomonitoring programs, both recent and ongoing, to evaluate environmental exposure of humans to
chemicals. Due to the lack of exposure and kinetic data, the correlation of biomarker levels with exposure concentrations
leads to diﬃculty in utilizing biomonitoring data for biological guidance values. Exposure reconstruction or reverse dosimetry
is the retrospective interpretation of external exposure consistent with biomonitoring data. We investigated the integration of
physiologically based pharmacokinetic modelling, global sensitivity analysis, Bayesian inference, and Markov chain Monte Carlo
simulation to obtain a population estimate of inhalation exposure to m-xylene. We used exhaled breath and venous blood m-
xylene and urinary 3-methylhippuric acid measurements from a controlled human volunteer study in order to evaluate the ability
of our computational framework to predict known inhalation exposures. We also investigated the importance of model structure
and dimensionality with respect to its ability to reconstruct exposure.
1.Introduction
There are numerous programs, recent and ongoing, to eval-
uate environmental exposure of humans to chemicals, for
example, EU ESBIO, COPHES, US CDC NHANES, Cana-
dian Health Measures Survey [1–4]. Exposure assessment is
relatively simple for occupational situations but more com-
plex for the general public where exposure occurs via poorly
deﬁned exposure scenarios and multiple pathways. Under
such circumstances human biological monitoring (BM or
biomonitoring)canbethemostreliableexposureassessment
methodology as it provides an estimate of internal or ab-
sorbed dose of chemical by integrating exposure from all
routes [5]. BM is the repeated controlled measurement
of a chemical, its metabolites, or biochemical markers in
accessible samples such as bodily ﬂuids (e.g., urine, blood,
saliva), exhaled air, and hair [6]. In risk characterisa-
tion, BM is often superior to other methods of exposure
assessment, such as personal air measurements or dermal
deposition assessments, because actual estimated body bur-
den or biologically eﬀective dose is a composite measure
of the diﬀerences in individual behaviour (e.g., personal
hygiene), work rate (characterised by diﬀerent respiration
rates), physiology, metabolism, and hence susceptibility [5].
Uncertainty in external exposure assessment due to inter-
and intraindividual variability can also be reduced by using
BM if the measured biomarker, either parent chemical or
metabolite, is proportionately related to the ultimate toxic
entity [5].
It has been proposed that the eﬀects on public health
from exposure to environmental chemicals may be better
understood when the relationships between key events along
the exposure-health evaluation-risk assessment continuum
are established [7]. BM is one such tool that can link external
exposure and biologically eﬀective dose. Unfortunately, it
is more often the case that BM data are reported without2 Journal of Toxicology
the corresponding external exposure data, which then re-
quires deﬁnition of the relationship with biologically eﬀec-
tive dose. “Exposure reconstruction” or “reverse dosimetry”
are terms used to describe procedures for determining esti-
mates of external exposure consistent with BM data.
There have been a number of studies in which phys-
iologically based pharmacokinetic (PBPK) modelling and
statistical techniques were used to “reconstruct exposure
or dose” consistent with human BM data at both the
individual and population levels [8–15]. Population-based
estimatesofexposurethataccountforhumaninterindividual
variability, both in the modelling of chemical disposition
in the body and in the description of plausible exposure
conditions, can be achieved using the Bayesian inference
[10].Gelmanetal.[16]usedaBayesianapproachasageneral
method of parameter estimation in PBPK models. This
method was originally applied to PBPK model calibration
[17–20] .L y o n se ta l .[ 10] extended PBPK model calibration
toincludetheuniqueexposureforeachindividualasanother
parameter to be estimated, alongside two additional “hyper-
parameters”, the mean and standard deviation of exposures
at the population level, to model variability in exposure. In
this way the model could be applied to interpret population-
based BM data.
The use of a PBPK model is signiﬁcant because all
the parameters represent anatomical, physiological, and bi-
ochemical characteristics which constrain variability to
within biologically plausible limits. The limits on variability
bestowed by biological structure suggest that the “ill-posed”
problem of reverse dosimetry can be addressed to a certain
extent. The ill-posed problem refers to the situation where
any number of reverse dosimetry outcomes (reconstructed
exposures) are possible, for example, an unstable model
where a small change in the data may lead to a large change
in output of the inverse function or no unique solution,
and therefore a myriad of possible solutions or no solution
at all ([21] cited by Lyons et al. [10]). Instead, knowledge
regarding ranges, central values, and measures of dispersion
are ascribed to model parameters, which are combined with
speciﬁc data from separate studies to deﬁne informative
prior distributions. Therefore, the linking of a PBPK model
with Bayesian inference has a number of advantages with
regardtoexposurereconstruction.Firstly,itisanappropriate
approach for systems where tissue dose is not necessarily
linearly related to external exposure [10, 22, 23]. Secondly,
deﬁning informative prior distributions around parameters
converts a deterministic model to a population model.
Thirdly, this combination can extract population variability
and multiple routes of exposure information integrated
within BM data.
The use of a PBPK model to link BM to external ex-
posures has already been described as signiﬁcant. However,
an aspect of exposure reconstruction that has not yet been
adequately explored is whether any particular model is an
adequate representation of the biological system it is built
to emulate. If there are inadequacies in the PBPK model,
then the exposure estimates will be wrong. By using data
generated from a laboratory study where both the BM
outputsandtheexposureareknown,exposurecanbetreated
as an unknown variable to be estimated from the data, which
allows the PBPK model to be evaluated and any inadequacies
to be addressed. Whilst comparable data from laboratory-
based studies are not a prerequisite for population-based
modelling, indeed for chemicals with adverse health eﬀects
such data will not be available, human volunteer studies
provide much richer data than will be available for pop-
ulation-based modelling. Within this environment it is
possible to study how contextual information about indi-
viduals, in addition to samples, improves the results of dose
reconstruction, the eﬀect of interindividual variability on
biomarker proﬁles can be studied, and the use of a PBPK
model alongside new data streams, such as the exhaled-
breath measurements used in this study, can be validated.
The results from controlled laboratory-based studies for a
variety of chemicals and exposure scenarios could inform
improvements in population-based modelling.
In this study we used a PBPK model to evaluate the
reconstruction of inhalation exposure to m-xylene from ex-
perimental BM data obtained in a controlled human volun-
teer study. Biomonitoring data comprised of timed measure-
m e n t so fv e n o u sb l o o da n de x h a l e dm-xylene and urinary
3-methylhippuric acid (MHA). In addition, we investigated
the reconstruction of inhalation exposure when using the
individual volunteer anthropometric measurements of body
mass, body fat mass, resting alveolar ventilation rate, urine
ﬂow, urine creatinine concentration, and blood:air partition
coeﬃcient in addition to BM data. We also investigated the
use of global sensitivity analysis [24] to reduce the compu-
tational cost of reverse dosimetry which, depending on the
selected model output, is achieved by setting unimportant
parameters of the PBPK model to central estimates.
2.MaterialsandMethods
2.1. Volunteers. The UK Health and Safety Executive Re-
search Ethics Committee approved the study. Volunteers,
who all were Health and Safety Laboratory staﬀ,p r o v i d e d
written informed consent before participating. Eight vol-
unteers, 7 male and 1 female (aged 29 to 54) (Table 1),
took part, were in good health at the time of the study, did
not suﬀer from respiratory disease, and were not on any
medications. Medical assessments were made immediately
before the start and at the end of each experiment, to
ensure that each volunteer was ﬁt to participate and then
to be discharged, respectively. The medical supervisor was
present throughout the exposure period. All volunteers were
asked to refrain from alcohol consumption for at least 72h
before entering the study. Body mass, height, body mass
index (BMI), mass of body fat, resting minute volume,
mean urine ﬂow, urinary creatinine concentration, and m-
xyleneblood:airpartitioncoeﬃcientforeachvolunteerwere
measured (Table 1). Body fat was estimated using a bio-
electrical impedance analyser (Bodystat 1500 Ltd., Isle of
Man, UK) and by skinfold thickness measurements (Holtain
callipers, Holtain Ltd, Crymych, UK). The value for mass of
body fat used was the mean of the two techniques. Resting
minute volume was measured using a Morgan Medical
Pulmolab TF 501 apparatus at the Respiratory FunctionJournal of Toxicology 3
T
a
b
l
e
1
:
I
n
d
i
v
i
d
u
a
l
v
o
l
u
n
t
e
e
r
p
a
r
a
m
e
t
e
r
s
.
V
o
l
u
n
t
e
e
r
A
g
e
B
o
d
y
w
e
i
g
h
t
(
B
W
)
(
k
g
)
H
e
i
g
h
t
(
m
)
B
M
I
(
k
g
/
m
2
)
M
a
s
s
o
f
b
o
d
y
f
a
t
(
V
f
a
C
)
(
%
(
B
W
)
)
R
e
s
t
i
n
g
a
l
v
e
o
l
a
r
v
e
n
t
i
l
a
t
i
o
n
r
a
t
e
(
Q
P
C
)
(
l
/
h
r
)
U
r
i
n
e
ﬂ
o
w
(
R
u
r
i
n
e
)
(
l
/
h
r
)
U
r
i
n
a
r
y
c
r
e
a
t
i
n
i
n
e
(
C
R
E
)
(
m
m
o
l
/
l
)
m
-
X
y
l
e
n
e
b
l
o
o
d
:
a
i
r
p
a
r
t
i
t
i
o
n
c
o
e
ﬃ
c
i
e
n
t
(
P
b
a
)
A
5
4
7
9
1
.
6
8
2
8
.
0
0
0
.
2
1
8
3
8
3
.
3
0
.
0
7
0
1
4
.
8
1
5
.
1
B
5
1
6
1
.
5
1
.
7
8
1
9
.
3
2
0
.
1
9
2
4
0
9
.
3
0
.
1
2
5
7
.
3
0
1
6
.
8
C
4
7
8
9
1
.
9
1
2
4
.
4
0
0
.
1
6
9
4
7
7
.
5
0
.
0
9
0
1
4
.
9
1
1
.
4
D
4
8
8
5
1
.
7
5
2
7
.
8
0
0
.
2
6
3
3
6
2
.
7
0
.
0
9
1
1
3
.
0
1
8
.
0
E
2
9
7
6
1
.
8
5
2
2
.
2
0
0
.
1
3
0
3
2
7
.
2
0
.
0
8
8
1
2
.
5
2
6
.
5
F
2
5
7
6
1
.
8
3
2
2
.
7
0
0
.
1
6
2
3
5
2
.
6
0
.
0
5
5
1
4
.
8
2
0
.
2
G
4
1
7
5
1
.
7
0
2
6
.
0
0
0
.
1
7
9
4
6
2
.
2
0
.
0
7
6
1
2
.
8
—
H
2
9
6
8
1
.
7
0
2
3
.
5
0
0
.
2
9
9
3
4
8
.
6
0
.
0
7
4
1
0
.
2
2
1
.
6
M
e
a
n
7
6
.
2
1
.
7
8
2
4
.
2
4
0
.
2
0
2
3
9
0
.
4
0
.
0
8
3
1
2
.
5
1
8
.
5
S
D
8
.
7
3
0
.
0
8
2
.
9
5
0
.
0
5
6
5
4
.
8
9
0
.
0
2
1
2
.
7
0
4
.
9
0
C
V
0
.
1
1
5
0
.
0
5
0
.
1
2
2
0
.
2
7
7
0
.
1
4
1
0
.
2
4
7
0
.
2
1
2
0
.
2
64 Journal of Toxicology
Unit of the Royal Hallamshire Hospital, Sheﬃeld. Alveolar
ventilation rate was assumed to be 70% of minute volume.
2.2. Chemicals. m-xylene (99%) and 3-methylhippuric acid
(MHA) (98%) were obtained from Aldrich Chemical Co.
(Dorset, UK). All other chemicals used were reagent grade
or higher.
2.3. Exposure Protocol. Exposures were performed in the
Health and Safety Laboratory Controlled Atmosphere Facil-
ity (CAF), a purpose built room 8m3 in volume. Purging
m-xylene-ﬁlled bubblers with compressed air into the CAF
generatedatmospheresofm-xylenevapour.Theatmospheric
concentration within the CAF was monitored continuously
with a Miran infrared spectrophotometer (calibrated by an
internal, closed-loop system) and by gas chromatography
(Varian 6000, with a 0.05m %0.5mm i.d., with 5% OV10,
100–120 mesh Chrom CHP packing; injector temperature
120◦C, N2 carrier gas ﬂow rate 40mLmin−1,o v e nt e m -
perature 60◦C) with ﬂame ionisation detection (detector
temperature 200◦C, H2 ﬂow rate 25mLmin−1,a i rﬂ o w
rate 300mL min−1, calibration using a gas sampling valve
against a standard atmosphere). The CAF temperature was
maintained at 25◦C and 30% humidity for all experiments.
Groups of 4 volunteers were exposed for 4h on two
separate occasions to a target concentration of 40 ppm m-
xylene vapour. The actual exposure concentrations for the
duration of the experiments were measured at 39.0 ± 3a n d
37.0 ± 2ppm, respectively.
2.4. Biomonitoring Data (BM). Blood (CV) and exhaled
alveolar (CXPPM) m-xylene and urinary MHA (Curine)
concentrations were measured. Volunteers provided blood
samples from the antecubital vein via an indwelling soft
cannula. Blood samples were stored (48 hours maximum)
at 4◦C as whole blood until analysed. Blood samples were
assayedinduplicateasfollows.A250μLsamplewasaddedto
750μLo fH 2O in a 10mL headspace vial, which was capped
with a PTFE-lined rubber septum. The sample was then
incubated and continually stirred at 65◦Cf o r1 0m i n u t e s .
A one mL headspace aliquot was taken using a warmed
(75◦C) gas-tight syringe (Fisons HS800 headspace sampler)
and analysed by gas chromatography (Carlo Erba GC8000;
column BP-5, 25m % 0.32mm i.d., 5μm ﬁlm) and mass
spectrometry (Fisons MD800 MS) operating in selected ion
monitoring mode using positive electron ionisation (m/z
[M+] 106). The limit of detection of the assay was 0.1μmol/l
with intra- and interassay coeﬃcients of variation of 5 and
10%, respectively.
End tidal breath samples (alveolar air) were taken and
analysed according to the method of Dyne et al. [25]
described previously [26].
Urine volume was recorded and samples were stored
at −20◦C until analysed. The major metabolite, MHA, was
measured in the urine to assess the rate of biotransformation
and elimination of m-xylene. A 0.5mL sample of urine
was mixed with 0.5mL methanol and analysed by HPLC
(Hewlett Packard 1050 Series, with autosampler, pump,
degasser; column 3μm ODS, 100 % 4.6mm) with a mobile
phaseof0.1%aceticacid:methanol(85:15withgradientelu-
tion), using diode array detection at a detection wavelength
of230nm.Thelimitofdetectionoftheassaywas40μmoll−1
with intra- and interassay coeﬃcients of variation of 2 and
5%, respectively. Creatinine concentration was measured by
using a Cobas Mira (ABX France) and an automated alkaline
picrate method [27]. The coeﬃcient of variation for intraday
analysis was 1.5% and for interday analysis was 3% at 6mM.
Venous blood samples were taken at 0, 1, 2, 3, 4, 4.33,
4.67, 5, 6, 7, 8, and 23 hours. The blood data were separated
into two sets corresponding to measurements made on
diﬀerent occasions to investigate the importance of data
quality in reverse dosimetry (Figures 1(a) and 1(b)). The
analysts explain that blood data deemed unreliable may
be due to imperfect sealing of sample vials leading to
losses. This explanation is plausible when compared to the
appearance of the exhaled breath and urine data for all
volunteers, which are qualitatively similar. Also, the peak
CV concentrations of the reliable data are quantitatively
and qualitatively comparable with data from similar human
volunteer studies [28, 29].
Exhaled air samples were taken at 0, 4.017, 4.33, 4.67, 5,
6, 7, 8, and 24 hours (Figure 2). Urine samples were taken at
0, 4, 6, 8, 10, 12, 14, 24, 27, and 31 hours (Figure 3).
Anthropometric measurements for each volunteer are
listed in Table 1.
2.5. The PBPK Model. A human PBPK model that includes a
bladder compartment to simulate ﬂuctuations in metabolite
concentration in urine caused by micturition [30]w a s
adapted to study the inhalation pharmacokinetics of m-
xylene. Liver, adipose, richly and slowly perfused tissues,
and the bladder represent the body (Figure 4). The model
parameter abbreviations and point values, which are similar
to previous models, are listed in Table 2 along with the
distributions used in the sensitivity analysis (SA) [26, 31].
Exhalation, metabolism, and renal excretion were the routes
of elimination. The concentration of unbound MHA, the
main metabolite of m-xylene in the blood, assumed to
be equivalent to the concentration of compound ﬂowing
throughthekidneywasdescribedbythefollowingequations:
d(MHAB)
dt
=
 
MRLi ×
MWMHA
MWxyl
 
−(MHAB ×K1),
d(MHAU)
dt
= MHAB × K1,
MRLi =
Vmax ×CVLi
KM + CVLi
,
Curine =
MHAU
VolU ×CRE
,
(1)
where MRLi is the rate of metabolism of m-xylene to MHA
in the liver, MWMHA and MWxyl are the molecular weights
of MHA and m-xylene, respectively, MHAB is the amount
of MHA in the blood, K1 is a ﬁrst-order elimination rate
constant describing removal of MHAB from the blood to
the urine, Vmax is the limiting rate and KM is the Michaelis-
Menten constant for hepatic metabolism of m-xylene, CVLi
is the hepatic venous eﬄuent concentration of m-xylene,Journal of Toxicology 5
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Figure 1: (a) Venous blood concentrations of m-xylene. Data from three volunteers were prepared and measured on a diﬀerent day than
other four. This set of data has the expected appearance and was considered acceptable for use in reverse dosimetry. (b) Venous blood
concentrations of m-xylene. Data from four volunteers were prepared and measured on a diﬀerent day than other three. This set of data does
not have the expected appearance and was considered unacceptable for use in reverse dosimetry.
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Figure 2: Exhaled m-xylene. Data from eight volunteers used in
reversedosimetry.Thedatapointsenclosedwithinthegreybarwere
excluded from the ﬁnal exposure reconstruction simulations.
MHAU is the amount of MHA in the urine, VolU is the
volume of urine in the bladder, and CRE is the concentration
of creatinine. The concentration of MHA in the urine was
expressed in mmol/mol creatinine. To imitate micturition,
the bladder is assumed to ﬁll with urine at a constant
(but adjustable) rate and empty at discrete time intervals
(when the volume of urine reduces to zero). This enables
comparison to be made between model predictions and
experimental observations with timed sampling in human
volunteer studies [30].
The Michaelis-Menten constant KM and the in vitro Vmax
for hepatic metabolism of m-xylene were obtained from the
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Figure 3: Urinary 3-methylhippuric acid (MHA). Urinary excre-
tion of MHA expressed against creatinine for eight volunteers used
in reverse dosimetry.
literature [32]. In vitro-in vivo extrapolation of Vmax was
obtainedbymultiplyingtheinvitrovaluebyahumanhepatic
microsomal protein yield (MPY) of 32mg g−1 wet weight
liver and the mass of liver (MLi)( g )[ 33, 34]:
in vivo Vmax = in vitro Vmax ×MPY ×MLi. (2)
2.6. Parameter Distributions. Anatomical and physiological
parameter distributions used for SA and MCMC simu-
lations listed in Table 2 were obtained from the freely6 Journal of Toxicology
Table 2: Anatomical, physiological, and kinetic constants and parameters used in the PBPK model.
Parameter Abbreviation Value Distribution
Molecular mass m-xylene (g/mol) MWxyl 106.17 —
Molecular mass MHA (g/mol) MWMHA 193.2 —
Body mass (kg) BW Normal BW∼N(76.2, (8.73)2)
Vascularised tissue (proportion of body mass) VT 0.91 —
Cardiac output (L h−1 BW−0.75)Q C C N o r m a l Q C C ∼N(13.8, (2.5)2)
Metabolism (Liver)
In vitro Michaelis constant (mMol L−1) KM Normal KM ∼N(11.8, (1.4)2)
In vitro maximum rate of metabolism (pmol min−1 mg−1
microsomal protein) Vmax Normal Vmax ∼ N(895, (68)2)
Microsomal protein yield per gram wet weight liver (mg g−1) MPY Lognormal ln (MPY)∼N(3.7, (2.9)2)
Gas exchange
Respiratory rate (L h−1)Q P C N o r m a l Q P C ∼N(390.4, (54.9)2)
Respiratory dead space (proportion respiratory rate) DS 0.3 —
Partition coeﬃcient
Blood:air partition coeﬃcient Pba Normal Pba∼N(18.5, (4.9)2)
Rapidly perfused Prpda Uniform Prpda∼U(50–150)
Slowly perfused Pspda Uniform Pspda∼U(40–80)
Adipose Pfaa Uniform Pfaa∼U(1400–2200)
Liver Plia Uniform Plia∼U(150–350)
Tissue blood ﬂow as a fraction of cardiac output
Rapidly perfused QrpdC 0.48 —
Slowly perfused QspdC 0.22 Uniform QspdC∼U(0.2–0.35)
Adipose QfaC 0.05 Normal QfaC∼N(0.053,(0.003)2)
Liver QliC 0.25 Normal QliC∼N(0.271,(0.01)2)
Tissue mass as a fraction of body mass
Rapidly perfused VrpdC 0.09 —
Slowly perfused VspdC 0.604 —
Adipose VfaC 0.19 Lognormal
ln(VfaC)∼N(−1.59,(−2.88)2)
Liver VliC 0.0257 Normal VliC∼N(0.036,(0.01)2)
Bladder compartment
Rate of urine production (L h−1)R urine 0.07 Normal Rurine ∼ N(0.083,(0.021)2)
Urinary creatinine concentration (mmol L−1) CRE 12.5 Normal CRE∼N(12.5,(2.7)2)
First-order elimination rate constant (h−1) K1 Uniform K1 ∼U(5–20)
available web-based application PopGen, which is a vir-
tual (healthy) human population generator (http://xnet.hsl
.gov.uk/popgen/). A human population, comprising 50%
male and 50% female, white Caucasians, age range 16–
65, height range 140–200cm, body mass indices 18.5–
30, was generated to encompass the characteristics of the
volunteers that took part in the study described below.
In PopGen, organ masses and blood ﬂows are determined
for virtual individuals from both ap r i o r idistributions of
anthropometric parameters such as body mass, height, and
body mass index and measured data from existing studies.
The algorithms were derived and evaluated by Willmann
et al. [35].
No distributions were available for the partition coef-
ﬁcients (PCs) Prpda, Pspda, Pfaa,a n dPlia. Therefore,
uniform distributions were assigned and the ranges set were
considered reasonable assumptions. VspdC and VrpdC, the
massesoftheslowlyandrapidlyperfusedtissuesrespectively,
were not included in the SA because they are aggregated
compartments from which organs and tissues are subtracted
when discretely deﬁned during model building. The model
was re-parameterised as proposed by Gelman et al. [16]t o
ensure that mass balance and blood blow constraints were
not violated.
The mean value for K1, the ﬁrst-order elimination rate
constant describing removal of MHAB from the blood to the
urine, was estimated by simulating the postexposure urinary
excretion of methylhippuric acid following exposures at 1–
10, 11–20, 21–30, and 31–40ppm [36]. The four datasets
were digitised and K1 estimated using the quasi-NewtonJournal of Toxicology 7
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Figure4:SchematicofthePBPKmodelform-xylenewithabladder
compartment, to simulate ﬂuctuations in the concentration of the
main metabolite, methylhippuric acid.
algorithm within acslX Libero. The mean value for K1 was
used in all simulations as sensitivity analysis demonstrated
the model output; in this case urinary excretion of methyl-
hippuric acid was relatively insensitive to this parameter.
2.7. Sensitivity Analysis. The extended Fourier amplitude
sensitivity test (eFAST) for the quantitative sensitivity anal-
ysis (SA) of model parameters and the presentation of SA
results as Lowry plots have been described previously [24].
The sensitivities of CV and CXPPM at the 3- and 5-hour
time points within the distribution and elimination phases,
respectively, and at 5 and 8 hours for Curine in the early and
latter urinary elimination phases are reported. Sensitivity
analysis results were computed on a much ﬁner timescale.
However, the two time points selected for reporting were
broadly representative of the SA results: from 0 to 4 hours
absorption into the body and the period after 4 hours
elimination from the body for CV and CXPPM, 4 to 8 hours
“rapidelimination,”andafter8hours“returntobaseline”for
Curine.
2.8. Calibration. A distribution of plausible exposures was
achieved through calibration of the sensitive parameters of
the PBPK model using the human volunteer data, a process
referred to as reverse dosimetry. Speciﬁcally, this required a
comparison of the time-varying model predictions of con-
centrations of substance in blood (CV), breath (CXPPM),
and urine (Curine) with measurements in these media.
The output from the PBPK model was represented by
μij = η
 
xj,θj,λ,ti
 
,( 3 )
where μij is the corresponding model prediction for subject
j at time ti, xj represents the vector of anthropometric
measurements, and θj represents the vector of unknown
variables for subject j.V e c t o r sx and θ represent the vectors
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Figure 5: A comparison of 5 CV biomarker proﬁles corresponding
to parameter sets sampled from the priors and reliable CV meas-
urements.
of anthropometric measurements and unknown parameters
for all subjects, respectively. Parameter λ represents the
(presumed) unknown exposure concentration and ti indexes
aspeciﬁctime.SAwasusedtosimplifythePBPKmodelprior
to attempting calibration. Individualised parameters were
onlyascribedtothemostimportant(sensitive)parametersin
the model, whereas parameters that the model was relatively
insensitivetowereassumedtobecommontoallsubjectsand
ﬁxed at central values within their plausible ranges (Table 2).
As the data were obtained in a laboratory-based study, a
common exposure to all participants was assumed. More
intricate hierarchical models of exposure are required to
account for the heterogeneity of exposure for population
studies [10].
An inﬁnite family of parameter sets, which are inputs
to the PBPK model, are deﬁned by the (prior) probability
distributions on model parameters. Each parameter set is
used to overwrite the initial (default) parameters, thereby
constituting a diﬀerent PBPK model. In Figure 5 the reliable
CV measurements and the biomarker proﬁles corresponding
to 5 parameter sets drawn from the prior distributions of the
model parameters are shown. Each PBPK model speciﬁed
by a particular parameter set is unique; however, very
diﬀerent sets of parameters may deﬁne similar PBPK models
(with respect to speciﬁc model outputs). The objective of
the reverse dosimetry is to calibrate or tune the unknown
parameters of the model θ and the exposure concentration
λ such that the observational data and model predictions
are in close agreement. Convergence to a unique solution
was not possible (due to both measurement error and
model inadequacy); however, calibration should result in a
substantial reduction in the domain of the family of models
that are consistent with measurements. Formally, inference
was achieved through application of the Bayes theorem.
The posterior distribution results in a narrower range of
biomarker proﬁles than that depicted in Figure 5.
A model that linked model predictions to observations
was required. The considerations in choosing an appropriate8 Journal of Toxicology
form were that the model predictions and observations in
subjectsarestrictlynonnegative;themagnitudeofprediction
errors was proportional to the magnitude of the substance;
prediction errors were asymmetric, with observations much
greater than predicted by the model more likely than obser-
vations far below the model predictions. These features all
suggest that a model on the log scale was appropriate. Here,
as in other works [10, 15, 16] a lognormal distribution was
assumedformodellingtheprobabilisticrelationshipbetween
model predictions and observations.
Letting yij denote a measurement made on the jth sub-
ject at time i,w h e r eμij is the corresponding model pre-
diction, the likelihood based on all individuals at all measure-
ment times is written as
f
 
y | θ, λ, σ
 
=
J  
j=1
T  
i=1
1
√
2πσ2 exp
⎡
⎢ ⎣−0.5
⎛
⎝
ln
 
yij
 
−ln
 
μij
 
σ
⎞
⎠
2⎤
⎥ ⎦
. (4)
The likelihood is a function of both parameters and data.
This introduces a ﬁnal unknown parameter σ, which is a
statistical measure of the goodness of ﬁt.
The Bayes theorem was applied. This states that the
posterior distribution of the model parameters (θ, λ,a n dσ)
is proportional to the product of the likelihood and the prior
(which is itself the product of the priors for θ, λ,a n dσ). The
posteriordistributionisarepresentationofpriorbeliefs(and
constraints on parameters) updated by data:
f
 
θ, λ, σ | y
 
∝ f
 
y | θ, λ, σ
 
× f (θ) × f(λ) × f(σ).
(5)
Priordistributionsfortheθj aregiveninTable 2.Whilsteach
individual has a unique physiology, the same set of prior
distributions modelled the uncertainty in each individual
physiological parameters. However, whilst common prior
distributions were assumed, the subjects had unique pos-
terior distributions (informed by their personal BM data).
A uniform prior on the (presumed unknown) exposure
concentration between 0 and 200ppm was assumed; the
upper limit of this distribution was chosen such that the
prior distribution should have no inﬂuence on the posterior
distribution of λ. A noninformative prior (a uniform prior
on the positive real line for ln σ) was assumed for σ.
2.9. Inference. The form of the posterior distribution (5)
is complex because the PBPK model requires a numerical
solution, and this could not be obtained in closed form.
Inference about the parameters of the model was made using
a Markov chain Monte Carlo (MCMC) sampling algorithm
[37]. A single-component Metropolis-Hastings algorithm
w a su s e dt od r a ws a m p l e s .
The samples from (5) index an updated family of PBPK
models that are consistent with prior beliefs and laboratory-
based observations on subjects.
2.10. The Simulations. The simulations were designed to
investigate the precision of reconstructed exposures whilst
Table 3: Summary of simulations.
Simulations
Number of updated parameters
CV CXPPM Curine
Full set (mean values) 0 — 17
Most inﬂuential 11 11 11
Most inﬂuential-(x) 876
Parameters not updated
Measured parameters (x)
QPC QPC QPC
PBA PBA PBA
BW BW BW
VfaC Rurine
CRE
minimising computational cost and reducing the number
of inﬂuential unknown model parameters. A reduction
in computational burden was achieved primarily through
SA, with distributions ascribed only to those parameters
with a signiﬁcant contribution to model output variance.
The use of the anthropometric measurements (x)l i s t e di n
Table 1 allowed a reduction in the number of unknown
and important parameters. The simulations analysed were
therefore as follows.
(1) Computational cost and the reliability of SA analysis
were investigated by comparing the precision of two
simulations where exposure was reconstructed from
Curine. The ﬁrst updated 17 parameters and the
second updated the 11 most important parameters.
(2) ExposurereconstructionfromCV byupdating the11
most important parameters.
(3) Exposure reconstruction from CV using the 11 most
important parameters where eight were updated and
threewereindividualanthropometricmeasurements.
(4) Exposure reconstruction from suspect CV data using
the 11 most important parameters where eight were
updated and three were individual anthropometric
measurements.
(5) Exposure reconstruction from CXPPM using the 11
most important parameters.
(6) Exposure reconstruction from CXPPM using the 11
most important parameters where seven were updat-
ed and four were individual anthropometric mea-
surements.
(7) Exposure reconstruction from Curine by using the 11
most important parameters where six were updated
and ﬁve were individual anthropometric measure-
ments (including individual Rurine and CRE mea-
sured at each sampling time).
The simulations and speciﬁc anthropometric measure-
ments used are listed in Table 3.
2.11. Software. The numerical solutions to the model equa-
tions were obtained using acslX Libero version 3.0.1.6 (AEgisJournal of Toxicology 9
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(b) CXPPM, 3 hours
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(c) Curine, 5 hours
Figure 6: Lowry plot of the eFAST quantitative measure. The total eﬀe c to fap a r a m e t e rSTi comprised the main eﬀect Si (black bar) and
any interactions with other parameters (grey bar) given as a proportion of variance. The ribbon, representing variance due to parameter
interactions, is bounded by the cumulative sum of main eﬀects (lower bold line) and the minimum of the cumulative sum of the total eﬀects
(upper bold line), (a) CV at 3 hours, (b) CXPPM at 3 hours, (c) Curine at 5 hours.
Technologies; http://www.acslx.com/). The M functions for
eFAST and MCMC modelling included with the acslX
optimum suite of tools were adapted for use in this study.
Lowry plots and histograms were created using R and
ggplot2 [38, 39] with additional code by Takahashi [40].
Data were digitised using Grab It! Graph Digitizer (Data-
Trend Software, Inc.; http://www.datatrendsoftware.com/).
ThecomputerusedinthisstudywasaDellOptiplex755Intel
Core 2 Duo CPU 3.00GHz 2.00GB RAM.
3. Results
3.1. Sensitivity Analysis. Figures 6(a), 6(b),a n d6(c) are
typical Lowry plots for CV and CXPPM at 3 hours and Curine
at 5 hours used to select the most inﬂuential parameters.
The total eﬀect of a parameter STi comprised the main eﬀect
Si (black bar) and any interactions with other parameters
(grey bar) given as a proportion of variance. The ribbon,
representing variance due to parameter interactions, is
bounded below by the cumulative sum of main eﬀects (lower
bold line) and above by the minimum of the cumulative
sum of the total eﬀects and one minus the sum of the
main eﬀects that were not included (upper bold line). The
most inﬂuential parameters were selected by reading across
from the 95% variance point on the y-axis to the upper
bold line and then down to the x-axis. All parameters to
the left of this point were selected and used in the dose
reconstruction. The most inﬂuential parameters at the latter
time points of ﬁve hours for CV and CXPPM and eight
hours Curine were selected in the same way (Lowry plots
not shown). In Table 4 the most inﬂuential parameters at
the latter time points are listed alongside those from the
earlier time points. The parameters in bold are those that
only become inﬂuential at the latter time points. These were
added to the parameters that were inﬂuential at the earlier
Table 4: Model parameters accounting for 100% variance at dif-
ferent time points.
CV CXPPM Curine
3h 5h 3h 5h 5h 8h
QPCa QPC Pba Pba Rurine Rurine
Pba QspdC QPC QPC CRE BW
KM KM QCC QspdC BW QPC
QCC QCC KM KM Pba CRE
QliC Pba QliC QCC KM VfaC
MPY QliC MPY Prpda QCC Qspdc
Pspda Prpda Pspda QliC MPY Pspda
BW MPY VliC MPY QliC Pba
VliC Pspda BW Pspda QPC QCC
QspdC VliC Pfaa
aItalicised abbreviations correspond to parameters measured for each
volunteer listed in Table 1.
time points in order to ensure that prior distributions were
assigned to all inﬂuential parameters across the entire time
period of interest. The measured parameters listed in Table 1
are also listed in Table 3 to indicate when they were used in
each simulation and are italicised in Table 4 to indicate when
they contributed to variance of dose metric.
3.2. Computational Cost and Reliability of SA (Simulation 1).
Initially, two simulations calibrating to the observed urine
measurements (Curine) from the volunteers were run. Both
simulations employed the distributions listed in Table 2.T h e
subset of anthropometric parameters listed in Table 1,w h e r e
measurements were available for each individual, was not
used in this ﬁrst stage; that is, xj was an empty set. The
two initial simulations diﬀered only in terms of the numbers10 Journal of Toxicology
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Figure 7: Comparison of estimated posterior distributions for 4-hour inhalation exposure to m-xylene. Posterior distributions were
estimated by updating the entire set of parameters, most inﬂuential parameters, or by ﬁxing the measured parameters and updating the
remaining most inﬂuential: (a) Curine, full parameter set, (b) Curine, most inﬂuential, (c) Curine, most inﬂuential and measured spot urine
production rates and creatinine concentrations.
of updated parameters for each individual; in the ﬁrst case
θj contained 17 unique parameters for each individual; in
the latter case θj contained the 11 most sensitive parameters
for each individual with the remaining parameters ﬁxed
at central values and common to all individuals (Table 3).
In addition, both models also contained the unknown
exposure, λ, and the statistical measure of ﬁt, σ.I nt o t a l ,
the models contained 138 ((17 ∗ 8) + λ + σ) and ((11
∗ 8) + λ + σ) parameters, respectively. The objective of
the comparison was to demonstrate that SA techniques
could be utilized before attempting a calibration in order
to reduce the dimensionality of the calculation, with only
a small loss of precision. The prior distributions for each
of the model parameters were common to all individuals
in both simulations. Prior distributions are given in Table 2
for physiological parameters. Prior distributions for the rate
of urine production and creatinine concentrations were
estimated from experimental data generated in the human
volunteer study (Table 1). The urine samples from the
individuals allowed their unique physiological parameters to
be updated, and posterior distributions were obtained for
all varying parameters for each individual. Typical posterior
distributionsforλestimatedfromCurine areshowninFigures
7(a), 7(b),a n d7(c). The mean, median, and a 95% interval
for λ and the posterior median for σ are listed in Table 5.
The posterior distributions for λ and σ were similar for the
modelsthatcontained138(Figure 7(a))and90(Figure 7(b))
unknownparametersrespectively;however,therewasasmall
diﬀerence in the central estimates for λ. This is entirely
consistent with the results of the SA and demonstrates
the value of appropriate SA techniques to the modeling
process.Therefore,furthersimulationswereconductedusing
models with prior distributions on only the most sensitive
parameters.
Due to the relatively small number of volunteers in the
study, it was computationally feasible to calibrate to large
numbers of individualized parameters for each subject. In
a population-based study, it is likely that a balance be-
tween precision (number of individualized parameters) and
computational cost would have to be achieved. For a
calibration using the urine data, Figure 6(c) indicates that a
calibrationmodelusingindividualizedparametersforthesix
most sensitive parameters would be adequate for capturing
the majority of variance during the rapid elimination phase;
however, additional parameters would be required in order
to capture a large proportion of the variance in the return
to baseline (slower elimination phase) period (Table 4). It
is important that contributions to the variance over the full
range of the measurements are considered.
3.3. Exposure Reconstruction from Venous Blood Biomarker
(Simulations 2–4). Two calibration models were ﬁtted to
each of the reliable CV, CXPPM, and Curine datasets. The
initial model did not include the measurements of the
anthropometric parameters listed in Table 1 (xj was an
empty set), whilst the second calibration model made use
of these data; therefore, there was a reduction in the vector
of uncertain parameters θj for each individual (Table 3).
Calibration models making use of the unreliable CV data
were also run to allow a comparison with the reliable CV
data.
The best estimates of exposure λ were obtained using
the reliable CV data from three volunteers (Data from the
fourth volunteer were not used due to problems with taking
blood samples.) although the 95% interval for λ was widest
using the reliable CV data, which can be explained by the
smaller number of volunteers and measurements (compared
with data from CXPPM and Curine). The central estimate of λ
was close to the target exposure of 37–39ppm (Figure 8(a)
and Table 5, reliable data, most inﬂuential), and model
predictions were consistent with the observed biomarker
proﬁle (discussed later on in results). There was a smallJournal of Toxicology 11
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Figure 8: Comparison of estimated posterior distributions for 4-hour inhalation exposure to m-xylene. Posterior distributions were
estimated by updating the most inﬂuential parameters or by ﬁxing the measured parameters and updating the remaining most inﬂuential:
(a) CV, most inﬂuential, (b) CV, ﬁxed, measured, and remaining most inﬂuential, (c) CV, most inﬂuential, using unreliable data.
improvement in the central estimate of λ after making use of
measured parameters x (comprising of QPC, Pba, and body
weight) for each subject; the 95% interval for λ (Figure 8(b)
and Table 5, reliable data, most inﬂuential including mea-
sured parameters) was shifted upward although the width of
the interval was unchanged.
Thechangeintheposteriordistributionofλthatresulted
from using anthropometric measurements can be attributed
to the correlations between λ and the measured parameters
x. Whilst the exposure concentration is ap r i o r iindependent
of physical parameters, it is correlated with these parameters
through the statistical model. In particular both QPC and
Pba were negatively correlated (correlations between both
QPC and Pba and λ were approximately −0.2 for each
individual) with the exposure concentration in the model
that treated these measured parameters as unknown. The
calibrationmodelisillposedandcannotdistinguishbetween
the case of a low exposure and eﬃcient transfer to the blood
(larger values of QPC and Pba), the case of a high exposure
and ineﬃcient transfer to the blood (smaller values of QPC
and Pba), or the continuum that exists between these two
extreme cases; all are consistent with the observed data.
Including measured values and thereby reducing the number
of uncertain parameters in the model reduced the domain
of models that were consistent with the venous blood data.
There was a small increase in σ when including measured
parameters x,ar e s u l to f9l e s s“ f r e e ”p a r a m e t e r st od e s c r i b e
the measurements.
Exposure reconstruction was also attempted using unre-
liable CV data from four volunteers (Figure 8(c) and Table 5,
unreliable data, most inﬂuential including measured param-
eters). The mean and median (17.4 and 17.3ppm) of the
exposure λ estimated from these data were approximately
half of the known exposure. The 95% interval for λ was
also very narrow. This is not a surprising ﬁnding as the
CV measurements (Figure 1(b)) were much lower and more
erratic compared with the reliable data (Figure 1(a)). It is
clear from visual inspection of Figures 1(a) and 1(b) that the
data in Figure 1(b) reach a peak at below 2μmol/l and qual-
itatively have an unusual proﬁle. As mentioned previously,
the analysts explain that this may be due to imperfect sealing
of sample vials leading to losses.
3.4. Exposure Reconstruction from Exhaled Breath Biomarker
(Simulations 5-6). Exposure reconstruction using the entire
CXPPM dataset resulted in a posterior distribution for λ
that was concentrated on a range well below the “true”
value (16.0, 15.8, 11.4, 21.4, mean and median, 2.5% and
97.5%, resp.). The simulation was repeated after excluding
the measurements made at 4 hours 1 minute (i.e., one
minute after exiting the exposure facility). Exclusion of
these measurements is justiﬁed because, during exposure
and immediately after leaving the source of exposure, the
concentration of solvent in breath reﬂects the portion of the
inhaled concentration that has not been absorbed, therefore,
is not representative of circulating blood solvent levels.
However, the posterior distribution for λ was not much
improvedafterexcludingtheﬁrstmeasurement(Figure 9(a))
and Table 5, most inﬂuential) although still well below
the target exposure. The model that included measured
anthropometric parameters had an almost identical central
estimate of exposure (Figure 9(b) and Table 5, most inﬂu-
ential, including measured parameters, x). The error σ was
similarly large for both of these models indicating that,
even at the estimated exposures, the ﬁt to the measurements
(discussed in Section 3.6)w a sp o o r .
3.5. Exposure Reconstruction from Urinary Biomarker (Simu-
lation 7). The ﬁrst three exposure reconstructions that were
attempted using the urine samples resulted in a posterior
distribution for λ that had similar central estimates of
exposure to those obtained from the reliable CV data.
This is not surprising because the rate of appearance of
metabolite in the urine was simulated using an empirical
rate constant, K1, which in eﬀect simply imposes a delay in
the appearance of metabolite in the urine from the blood.Journal of Toxicology 13
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Figure 9: Comparison of estimated posterior distributions for 4-hour inhalation exposure to m-xylene. Posterior distributions were
estimated by updating the most inﬂuential parameters or by ﬁxing the measured parameters and updating the remaining most inﬂuential:
(a) CXPPM, full parameter set, (b) CXPPM, most inﬂuential.
Themodelincludingmeasuredparameters,x,butwithmean
values for Rurine and CRE had a narrower conﬁdence interval
for λ compared with the initial models; this reduction in
uncertainty can be largely attributed to Rurine and CRE,
which sensitivity analysis showed were the most inﬂuential
parameters.
A modiﬁed PBPK model that allowed a time varying
rate of urine production was ﬁt to the data (Figure 7(c) and
Table 5, most inﬂuential, including measured parameters, x,
individual timed Rurine, and CRE). This model had a lower
central estimate for the exposure λ (mean and median; 29.0
and 28.9ppm, resp.), and the narrowest 95% interval for
λ (25.1 to 33.6). The target exposure was outside the 95%
interval using the most appropriate model (that reﬂects real
BM data, assuming that urine volumes would be recorded
during sample collection). The reasons for this ﬁnding are
discussed in the following section.
3.6. Validation and Model Criticism. A key assumption of the
calibration model was of independent, normally distributed
residuals (the diﬀerences between log model predictions and
log (CV, CXPPM, Curine) measurements. Model validation
was conducted to assess whether this assumption was
satisﬁed.
Calibration using data from (reliable) CV measurements
satisﬁed this assumption. Model predictions, from one
iteration of parameters from the MCMC algorithm and
corresponding measurements for three volunteers (A, C
and D), are shown in Figure 10(a). Given that the PBPK
model could predict the observed biomarker proﬁle suggests
that the model adequately describes the inhalation and
subsequent excretion of m-xylene from the blood.
For CXPPM the model assumption of normally dis-
tributed residuals was not satisﬁed.
Predictions from the PBPK model from one iteration
of parameters from the MCMC algorithm and correspond-
ing measurements for three (representative) volunteers are
shown in Figure 10(b). The ﬁgure demonstrates that the
model was unable to replicate the very rapid decay of m-
xylene in breath samples; the PBPK model proved to be
inconsistent with measurements for any combination of
model parameters. When using the data from CXPPM, the
MCMCalgorithmconvergedtoastationarydistributionthat
minimized the overpredictions from the model and clearly
the posterior distribution for λ is an unreliable estimate of
exposure. The biomarker proﬁles from the eight volunteers
were consistent and indicated that the measurements were
reliable; therefore, the issue is with the PBPK model. The
information from CV measurements gives some context to
interpretthisresultasthesedatahighlightthatthemodelcan
adequately describe the uptake, and indeed the elimination
of m-xylene, from the blood. Therefore, the PBPK model
currently lacks some biological detail for describing the
mechanism of exhalation of m-xylene. This is an area of
ongoing research.
Whilst the estimates of exposure using the Curine meas-
urements and the PBPK model with individualised urine
volume and creatinine measurements were close to the
target exposure, the assumptions of the calibration model
were not satisﬁed. Model predictions, from one iteration
of parameters from the MCMC algorithm and corre-
sponding measurements for three volunteers, are shown
in Figure 10(c). The model proved a reasonable ﬁt to
measurements taken between 8 and 14 hours but over-
predicted the initial elimination (4 and 6 hours) and14 Journal of Toxicology
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Figure 10: Model predictions for three volunteers from one iteration of the Markov chain and the associated measurements: (a) urine
predictions and data, (b) CV predictions and data, (c) CX predictions and data.
under-predicted the concentrations the following day (at 24,
27, and 30 hours). The large diﬀerence in results from the
model using the individualised urine volume and creatinine
measurements compared with the other PBPK models based
upon the urine measurements resulted from the former
model providing a better ﬁt to the measurements at 6 and
8 hours, whereas the latter models were a better ﬁt to
measurements at 24, 27, and 30. Given that the uptake of m-
xylene to the blood is adequately described, this suggests the
model lacks biological detail in the elimination of substance
in urine.
Elimination of m-xylene in urine has been studied over a
60-hour period [36]. The data from this study are consistent
with our own laboratory based study in showing that there
is an initial decay to a nonzero value (the ﬁrst 10 hours or
so after exposure has ceased) and a much slower elimination
of substance (taking in excess of 2 days) that follows. The
model may require a “deep tissue” compartment to simulate
the slower redistribution from fat and other tissue storage
compartments [41].
3.7. Additional Results. A model using the reliable CV data
with just the exposure concentration varying and all param-
eters ﬁxed at central values was run for comparison (Table 5,
all parameters ﬁxed at central values). Such a model does
not take human variability into account; the measurements
are all, in eﬀect, on the “mean human” with parameters
set at the central values listed in Table 2. The result was a
much lower central estimate of λ (24 and 23.8ppm, mean
and median, resp.), a narrower 95% conﬁdence interval for
the exposure (21–29ppm), and a larger median for ρ (0.55).
These latter two results are consistent with expectations. The
lower range of exposures resulted from the 3 volunteers not
beingrepresentativeofthe“meanhuman”(inparticularwith
respect to PBA and QPC).
This admittedly unusual result demonstrates that it
is important to recognise and model all known sources
of uncertainty. However, the large diﬀerence in the 95%
conﬁdence intervals between this and our ﬁtted models does
suggest that the prior distributions for the model param-
eters were too wide; the subjects in our study were more
homogeneous than the general population. More precise
results would have been obtained if prior distributions based
upon the study population had been adopted. In future work
a greater emphasis will be placed on understanding and
properly deﬁning the study population.
4. Discussion
In this paper it was demonstrated that SA techniques could
be used to reduce the dimensionality of the calibration
problem with a relatively small loss of precision. The use of
SA in this context is consistent with good modelling practice,
with SA used as an integral part of the modelling process
[42–45]. SA demonstrated that exposure reconstruction
using urine data requires a greater number of individualised
parameters in the PBPK model than either exhaled breath
or blood. This is not surprising as the PBPK model needs
to describe uptake, distribution, metabolism, and excretion
in order to reconstruct exposure using urine measurements,
and excretion from the body (in urine) takes in excess of
30 hours. More parameters are required to describe this
process, with some parameters only becoming important
at later periods (Table 4). In comparison the SA results for
blood and breath models were more consistent, the same
parameters were important throughout the full time-scale,
although the relative importance of parameters did change,
parameters governing uptake dominated during exposure,
and these became less important after exposure ceased. It
is important that the SA of the PBPK model covers theJournal of Toxicology 15
full period where measurements (for comparison with the
model) are available, so that the important parameters for
model calibration using the available data are identiﬁed.
The results from SA did inform one substantial improve-
ment in the description of urination in the PBPK model. It
was noted that the model was especially sensitive to Rurine,
the rate of urine production, and to a lesser extent CRE. The
initial PBPK model represented these as constants (either
unknown constants represented by probability distributions
or as constants estimated from measurements, depending
upon the model) for each individual. However, the experi-
mental data revealed that there were substantial variations
for each individual in both the rate of urine production and
CRE over the 31-hour period of the study. The PBPK model
was modiﬁed to allow time varying rates of Rurine and CRE.
Here it can be seen that SA techniques can be used to inform
model development as well as to reduce complexity. Also, the
results of SA can help inform the prioritisation of resources
and eﬀort in the generation of good-quality data.
Theaimofthis workwasnot toestimate themost precise
exposure for the subjects using all available measurements;
rather the aim was to reconstruct exposure using a single
measurement series and account for all signiﬁcant uncer-
tainties. This work can be viewed as an intermediate step
between laboratory- and population-based studies. Models
have been independently ﬁt to breath, blood, and urine
measurements, as these are a closer approximation to the
data from a population-based study. However, whilst the
models were independently ﬁt, a more complete picture
of the inadequacies of the PBPK model is obtained by
interpreting the results collectively.
Looking into the future, the greatest challenge is to
obtain estimates of a variable exposure concentration from
biological monitoring data available from individual “spot
samples,” typically at the end of a shift for workplace expo-
sures or at random times for environmental exposures. The
appropriate extension to the calibration model compared
with that used for data from our controlled laboratory
study is straightforward. Each individual will have a unique
exposure; a hierarchical model of exposure (Lyons et al.,
[10])canbeusedtoobtainacentralestimateandanestimate
of the variability in personal exposures. A greater challenge
is that in general a single sample per individual may be
available, and the time between the completion of exposure
and the production of a urine sample will vary. As this
study has shown, there is a strong correlation between the
length of time after exposure and the sample concentration
for nonpersistent and semipersistent chemicals (Figures 1,
2,a n d3). Based upon the data available from biological
monitoring, it will be very diﬃcult to isolate personal
exposures, after accounting for both biological variability
and time after exposure. An intricate calibration model will
b er e q u i r e d .T h i si sam a j o rc h a l l e n g ef o rf u t u r ew o r k ,
although empirical statistical models may prove a useful
tool. One option might be a two-phased approach: in the
initial phase, a nonlinear mixed-eﬀect model could be used,
with a mean corresponding to a PBPK model containing
the unknown exposure concentration as the sole unknown
parameter and systematic diﬀerences between humans
modelled by random eﬀects. The posterior distribution
for the exposure concentration from this ﬁrst phase could
provide an informative prior for the exposure concentration
in more detailed PBPK models. The precision of exposure
reconstruction would undoubtedly be improved if some
contextual information (relating to the time since the last
“signiﬁcant” exposure) accompanied each sample.
Although this work has focussed on the calibration prob-
lem with respect to the exposure concentration, the data
allow all the model parameters to be updated in light of the
data. This includes updating the parameters for each (exper-
imental) subject for quantities where population variability
is well characterised (such as organ sizes and blood ﬂows)
and quantities about which there is considerable uncertainty
in the general population. Some of the partition coeﬃcients
fell into this latter category; uniform distributions with
wide support were used as the prior distributions for the
partition coeﬃcients Pspda, Prpda, and Pfaa. In principle
the data would allow individualised partition coeﬃcients to
be estimated for each of the subjects. However, when there
is uncertainty about variability in the general population,
it is appealing to structure a model in order to learn
about population variability; this can be achieved using a
hierarchical model that incorporates a population mean and
standard deviation into the calibration model. However, in
this work the SA indicated that the model was insensitive
to these uncertain partition coeﬃcients, and these were
therefore ﬁxed at central values in the model.
Initial models using CV, CXPPM, and Curine data ignored
the subset of anthropometric parameters (listed in Table 1)
that were available for each individual, and it was possible
to compare the posterior distributions for these parameters
with the known values. The posterior distributions for these
parameters were similar to the priors: the data from subjects
did result in some small changes; however, due to the large
numberofuncertainparametersforeachindividual,coupled
with an unknown exposure, the changes were modest. For
body weight (BW), the fat mass (VfaC), the blood:air
partition (Pba) coeﬃcient, and alveolar ventilation (QPC),
in general the posteriors moved toward the known values
(compared with the priors), although there was only a
modest reduction in uncertainty compared with the prior.
This is consistent with expectations; as the PBPK model is
ill posed, a strong convergence to the known values for these
parameters could not be achieved.
Given that the priors were similar to the posteriors, it is
important to question the value of a fully Bayesian analysis
using an MCMC algorithm that updates the parameters
for each individual compared with a Monte-Carlo (MC)
algorithm that accounts for interindividual diﬀerences by
sampling from the priors. In this case a comparison of
prior and posterior distributions for individual parameters
is overly simplistic. A priori all parameters are independent,
whereas parameters are correlated in the posterior distri-
bution. This means that the multidimensional posterior is
av e r yd i ﬀerent shape to the multidimensional prior, even
though the marginal distributions are similar. Speciﬁcally,
a smaller domain of PBPK models is consistent with the
observed data after calibration. In cases where fewer data16 Journal of Toxicology
are available for calibration, MCMC will not oﬀer the same
improvements over MC sampling.
Throughoutthepaperwehaveusedthetermsuncertainty
and variability, which are important and related concepts.
There are numerous and wide ranging uncertainties in many
modelling scenarios. O’Hagan and Oakley [46] identify the
main components of uncertainty for computer models as
parameter uncertainty, model inadequacy, residual variabil-
ity, and code uncertainty. The various uncertainties in a
model can be described as aleatory uncertainties, which
arise from inherent variability or randomness in systems,
and epistemic uncertainties, which arise due to imperfect
knowledge. Oberkampf et al. [47] noted that a variety of
terms in the literature have been used to describe these two
classes of uncertainty; the terms irreducible (aleatory) and
reducible (epistemic) uncertainty have perhaps the greatest
clarity. Model inadequacy is a reducible source of uncer-
tainty, residual variability may contain both reducible and
irreducible uncertainties, and parameter value uncertainty
is generally irreducible [46]. Probability can represent both
reducible and irreducible sources of uncertainty.
Other authors use the term variability in place of
alleatory uncertainty; however, we feel that this lacks clarity
[48]. Variability is certainly closely related to alleatory
uncertainty and can be both a cause of and ar e s u l to f
alleatory uncertainty. This can be seen in parameter value
uncertainty, where interindividual diﬀerences (variability)
between humans (partition coeﬃcients, blood ﬂows, organ
masses, etc.) are represented by probability. There is param-
eter value (alleatory) uncertainty in a PBPK model for any
given human due to interindividual diﬀerences; the unique
parameters for any individual are unknown; only variation
acrossthepopulationisknown.Thenetresultisanincreased
variability in the outputs of that model, which arise from
the parameter value uncertainty. Epistemic uncertainty also
results in increased variability in model outputs.
In conclusion, the integration of PBPK modelling, global
SA, Bayesian inference, and Markov chain Monte Carlo sim-
ulation is a powerful approach for exposure reconstruction
from BM data. The use of global SA techniques could be
used to reduce the dimensionality of PBPK models with a
minimal loss of precision and with consequent savings in
computationalcost.Also,theuseofSAinthemodelbuilding
and calibration phases is consistent with good modelling
practice. However, the precision of posterior estimates of
exposure is exquisitely dependent upon the ability of the
PBPK model to characterise the chosen biomarker, which
in turn is also exquisitely dependent upon the extent of
biological detail captured in a PBPK model. Further work,
on the level of detail required to satisfactorily describe
renal elimination and exhalation of volatile biomarkers of
exposure, is required.
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